The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EIX, MDR and ATUS
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Edison International (NYSE: EIX) Class Period: February 23, 2016 to November 12, 2018 Lead Plaintiff Deadline: January 15, 2019
The complaint alleges that throughout the class period Edison International made materially false and/or misleading statements and/or failed to disclose that: (i) the Company failed to maintain electricity transmission and distribution networks in compliance with safety requirements and regulations promulgated under state law; (ii) consequently, the Company was in violation of state law and regulations; (iii) the Company’s noncompliant electricity networks created a significantly heightened risk of wildfires in California; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Get additional information about the EIX lawsuit: http://www.kleinstocklaw.com/pslra-1/edison-international-loss-submission-form?wire=3
McDermott International, Inc. (NYSE: MDR) Class Period: January 24, 2018 to October 30, 2018 Lead Plaintiff Deadline: January 15, 2019
The lawsuit alleges McDermott International, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) the Company was facing strong headwinds and would fail to meet revenue and earnings estimates; (2) there were material problems with the integration of the CB&I business; (3) certain CB&I projects were reasonably likely to incur higher costs; (4) as a result, the fair value of these CB&I projects would be materially impacted; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Get additional information about the MDR lawsuit: http://www.kleinstocklaw.com/pslra-1/mcdermott-international-inc-loss-submission-form?wire=3
Altice USA, Inc. (NYSE: ATUS) Class Period: Pursuant and/or traceable to the June 2017 Initial Public Offering Lead Plaintiff Deadline: January 18, 2019
The complaint alleges that the Offering Documents issued pursuant to the IPO failed to disclose and/or misstated material information, including that: (1) “The Altice Way” proprietary growth model previously developed in Europe and described in the Offering Documents as a means to achieve superior margin performance was falsely touting Altice’s capacity to face already existing highly competitive environments and ever-changing consumer behaviors; (2) Altice was suffering from aggressively growing competition both in Europe and the United States, directly causing negative and decelerating revenue and EBITDA growth and impacting Altice’s market share; (3) specifically, Altice was suffering from mismanaged rate events, regulatory compliance and poorly managed network and customer care both in its France and Portugal segments, thereby impacting its customer base and churn rate; (4) Altice USA could not simply replicate the “The Altice Way” in the U.S.; and (5) as a result, Altice USA’s Offering Documents were materially misleading at all relevant times.
Get additional information about the ATUS lawsuit: http://www.kleinstocklaw.com/pslra-1/altice-usa-inc-atus-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.